eFFECTOR Therapeutics (OTC:EFTR) Stock, Quote.Headers.trade-ideas

eFFECTOR Therapeutics

eFFECTOR Therapeutics Inc is a clinical-stage biopharmaceutical company focused on pioneering the development of a new class of oncology drugs referred to as selective translation regulator inhibitors (STRIs).

Wall Street US stocks

News

Eurozone

Commodities

Intraday Update

Markets

Trading Ideas

AGFY

ALIM

ALLR

AREB

EFTR

MLGO

Dow Jumps 300 Points; Alimera Sciences Shares Spike Higher

analysis-4937349

EFFECTOR Therapeutics shares are trading lower by 74% during Monday&#39;s session. The company announced that it has terminated its employees and will wind down its operations.

Why eFFECTOR Therapeutics (EFTR) Shares Are Down Over 70%

Earnings

Penny Stocks

Global

ACHL

ALUR

CADL

TCBP

U.S. stocks turned lower toward the end of trading, with the Dow Jones index falling more than 200 points on Thursday.

The Dow traded down 0.59% to 38,894.58 while the NASDAQ fell 0.10% to 16,261.88. The S&amp;P 500 also fell, dropping, 0.28% to 5,197.03.

Dow Dips Over 200 Points; RPM International Shares Fall After Q3 Results

EFFECTOR THERAPUTCS INC by eFFECTOR Therapeutics, Inc.

eFFECTOR Therapeutics Inc

eFFECTOR Therapeutics Inc Warrants (26/08/2026)

Google announced in a blog <a href="https://blog.google/products/news/associated-press-gemini-app/">post</a> on Wednesday that it&#8217;s broadening its collaboration with The Associated Press (AP) to further enhance <a href="https://www.benzinga.com/topic/gemini">its Gemini app</a>.
What Happened: Under the new collaboration, the Associated Press will provide Google with a feed of real-time information that the company will use to improve the usefulness of Gemini results.
&#8220;We believe AI is a transformative technology and we look forward to partnering with the news ecosystem to explore the benefits of AI and empower journalists,&#8221; the Alphabet Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>)(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>) subsidiary said.
Gemini is Google&#8217;s flagship AI chatbot, previously known as Bard. Google rebranded the conversational AI app in February 2024.
Check This Out: <a href="https://www.benzinga.com/25/01/42993561/is-openais-chatgpt-about-to-make-amazons-alexa-apples-siri-and-google-assistant-a-thing-of-the-past">Siri, Alexa And Google Assistant May Become A Thing Of The Past Thanks To ChatGPT Tasks — Here&#8217;s How To Use The New Feature</a>
Why It Matters: Google said the expanded collaboration is specifically aimed at users looking for up-to-date information. A lack of real-time information was one of the main complaints from early AI adopters using early-stage AI chatbots.
"AP and Google's longstanding relationship is based on working together to provide timely, accurate news and information to global audiences," said Kristin Heitmann, senior vice president and chief revenue officer of The Associated Press.
"We are pleased Google recognizes the value of AP&#8217;s journalism as well as our commitment to nonpartisan reporting, in the development of its generative AI products,&#8221; she added.
Price Action: <a href="http://benzinga.com/quote/goog">Alphabet shares</a> were up 3.3% at $197.36 at the time of publication Wednesday, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/real-estate/25/01/43008676/has-early-google-investor-shaquille-oneal-found-his-next-big-winner-in-tech-stocks">Has Early Google Investor Shaquille O&#8217;Neal Found His Next Big Winner In Tech Stocks?</a></li>
</ul>
Photo: courtesy of Google.

Tech

GOOG

GOOGL

Google Expands Collaboration With Associated Press To Deliver Up-To-Date Information In Gemini AI App

Ecopetrol Has Reached An Agreement To Reduce 50% Of The Conversion Cost For The Purchase And Sale Of ADRs In The United States; The Measure Is Temporary And Is Expected To Be Effective Until July 10, 2025

Union Bankshares (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UNB#NASDAQ">UNB</a>) reported quarterly earnings of $0.67 per share. This is a 1.47 percent decrease over earnings of $0.68 per share from the same period last year.

Union Bankshares Q4 EPS $0.67 Down From $0.68 YoY

WIIM

APPS

AXTI

COHR

EGHT

MSFT

MTSI

SHOP

SPCB

Shares of companies within the broader technology sector are trading higher amid overall market strength after CPI data was in line with estimates and core CPI rose by less than expected.

Akash Network (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">AKT</a>) founder Greg Osuri on Wednesday revealed an unexpected driver behind the increasing adoption of decentralized cloud solutions: a looming energy crisis related to the intensive computing demands of <a href="https://www.benzinga.com/topic/artificial-intelligence">artificial intelligence</a>.
While Akash Network was initially conceived as a decentralized alternative to traditional cloud providers, Osuri told Benzinga in an interview unforeseen challenges around energy capacity are now pushing its use into new, vital territories.
Osuri explained that the centralized data center model is facing severe limitations when it comes to providing the power required for advanced AI model training.
&#8220;People are not quite pricing in the energy limitations that we have. Just because you have more chips doesn&#8217;t mean you can actually use those chips," he said.
He further elaborated that major markets like the U.S. have trouble securing more than 10 megawatts of capacity, leading to an urgent need for more distributed, and potentially decentralized, solutions.
This energy bottleneck, Greg suggests, will force a shift to more decentralized infrastructure, with Akash being a central part of that change. 
"I think that is going to be such an unexpected reality. People are going to realize in two years. And then I think the decent AI is going to take off." 
Also Read: <a href="http://SEC Under Trump Administration To Revise Crypto Policies: Report">SEC Under Trump Administration To Revise Crypto Policies: Report</a>
Greg emphasized the increasing need to tap into individual homes and distributed networks, which the Akash Network is designed to support. 
"How do you go tap into individual homes? Is there a network that can actually let us go there? Yeah, that&#8217;s kind of the trigger, right?" he commented, outlining the decentralized imperative that his system uniquely addresses.
Beyond the energy concerns, Greg also spoke on the cost and sovereignty advantages of his system. 
He highlighted that the platform provides &#8220;10 times cheaper cost when it comes to CPUs&#8221; and that &#8220;Akash gets you H100 for 99 cents, same H100 will cost you $4,&#8221; making the platform four times cheaper for GPUs. 
Also, Greg stated the importance of transparency and availability through the network. "You want resources and you want guarantees that resources are going to be available."
Greg emphasized the open-source nature of Akash as another critical advantage, stating that &#8220;computer is a should be public utility&#8221; and that it &#8220;should not be, no one should tell you how to use it because you should have complete sovereignty.&#8221; 
The platform&#8217;s community-driven approach was also presented as a key competitive edge, fostering rapid innovation and network effects that are unattainable within single company structures.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/01/43008361/dubai-announces-crypto-tower-to-host-blockchain-businesses">Dubai Announces &#8216;Crypto Tower&#8217; To Host Blockchain Businesses</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$AKT

Akash Network Founder Reveals Unexpected AI Energy Crisis Driving Decentralized Cloud Adoption

Legal

Biden Administration Sues Southwest Airlines Over Chronically Delayed Flights

Editor&#8217;s note: This story has been updated to reflect that Bill Ackman&#8217;s social media post in support of Whitney Tilson&#8217;s candidacy for New York City mayor did not make a formal endorsement. 
Former hedge fund manager Whitney Tilson is running for mayor of New York City and he picked up a supporter in the form of Bill Ackman, one of the most recognized voices in th<a href="https://www.benzinga.com/topic/bill-ackman">e world of finance.</a>
What Happened: Tilson, who is an investor and editor at Stansberry Research, announced his run for mayor back in November, but a new video and Ackman&#8217;s backing could bring more attention to his fight against the incumbent mayor, <a href="https://www.benzinga.com/topic/eric-adams">Eric Adams, </a>and other candidates.
"Our great city is headed in the wrong direction," Tilson <a href="https://x.com/WhitneyTilson/status/1878814057790378175">said </a>in the video. "It's time to fight for New York's future."
The video shows images and article headlines of higher crime in the city, unsafe subways and residents hit hard with inflation. Tilson says in the video that thriving businesses are shutting down and families are leaving as they can't afford to live there, and the neighborhoods are no longer safe.
Tilson, who raised his family in New York City, expresses his confidence in the city's comeback in the video.
"I believe our best days are still ahead."
Tilson says he will represent "all New Yorkers" as mayor and help bring safety, affordability and prosperity back to the city.
"New York City is the greatest city in the world."
Ackman <a href="https://x.com/BillAckman/status/1878819267115712811">shared </a>the Tilson video and called the former hedge fund manager "the candidate to watch."
"I have known @WhitneyTilson since college. He has made a career giving back," Ackman tweeted.
Ackman said Tilson is a lifelong Democrat who is also "a smart economically rational one."
"He is pro-business, anti-waste and identity politics, and wants to make NYC great again."
Ackman said that people shouldn't want New York City to become San Francisco or Los Angeles and that Tilson can help save the city.
Read Also: <a href="https://www.benzinga.com/news/legal/24/07/40043812/edwin-dorsey-whitney-tilson-defend-andrew-left-positive-force-for-markets-and-the-pioneer-of-the-act">Edwin Dorsey, Whitney Tilson Defend Andrew Left: &#8216;Positive Force For Markets And The Pioneer Of The Activist Short Movement&#8217;</a>
Why It's Important: New York City Mayor Eric Adams was <a href="https://www.benzinga.com/news/24/09/41047664/fbi-raids-nyc-mayor-eric-adams-as-sealed-indictment-nears">indicted on federal charges</a> last year and awaits a trial after pleading not guilty. Adams became the first mayor in the city&#8217;s history to be charged with federal crimes while in office.
Tilson is one of several people running in the mayoral election that will be held in November 2025. Adams is currently running for re-election, but his indictment could put another win in jeopardy.
As a former hedge fund manager and investor, Tilson is well-known to many in the finance world, but he may be less familiar with other New Yorkers. Ackman&#8217;s support could help spread his platform to more people.
Tilson calls himself the only "change candidate" in the Democratic primary and also highlights that he is the only person running who isn't a career politician. Tilson also highlights his business background.
The campaign video shows Tilson's famous "60 Minutes" interview where he helped expose issues at Lumber Liquidators, a hardwood flooring company that went bankrupt in 2024.
A recent poll showed strong backing in the mayor race for former New York governor Andrew Cuomo at 32%, as reported by <a href="https://www.politico.com/news/2025/01/13/poll-cuomo-dominates-nyc-mayoral-field-00197761">Politico</a>. Cuomo has not announced his running in the election. Former city comptroller Scott Stringer received 10% of the vote with Adams getting 6%. Tilson was not listed in the poll results.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/12/42323060/nyc-mayor-eric-adams-takes-victory-lap-remember-yall-laughed-when-i-first-got-my-bitcoin-whos-laughing-now">NYC Mayor Eric Adams Takes Victory Lap: &#8216;Remember Y&#8217;All Laughed When I First Got My Bitcoin? Who&#8217;s Laughing Now?&#8217;</a></li>
</ul>
Photo: CK Foto via Shutterstock

Government

Politics

Bill Ackman Backs Former Hedge Funder Whitney Tilson For NYC Mayor: 'Can Help Save Us' (UPDATED)

The Japanese government bond (JGB) market is heating up, and some <a href="https://www.benzinga.com/topic/japan">analysts are sounding alarms</a>. 
What Happened: With the yield on Japan's 10-year JGB closing in on 1.25%, market observers are divided on the implications <a href="https://www.benzinga.com/money/investing">for global markets</a>.
Peter Schiff, chief economist at Euro Pacific Capital, has a grim outlook: "Soon it will be 1.5% and then 2%. Once the yield moves above 2%, JGBs could crash, sending yields soaring. This will create a financial tsunami that will crash U.S. financial markets."
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">No one seems to care, but the yield on the 10-year Japanese government bond is just under 1.25%. Soon it will be 1.5% and then 2%. Once the yield moves above 2%, JGBs could crash, sending yields soaring. This will create a financial tsunami that will crash U.S. financial markets.
&mdash; Peter Schiff (@PeterSchiff) <a href="https://twitter.com/PeterSchiff/status/1879183332136960243?ref_src=twsrc%5Etfw">January 14, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Read Also: <a href="https://www.benzinga.com/markets/25/01/42995151/bojs-kazuo-ueda-signals-rate-hikes-japanese-bond-yields-rise-to-14-year-high-what-the-recent-past-tells-us-about-impact-on-us-markets">BOJ&#8217;s Kazuo Ueda Signals Rate Hikes, Japanese Bond Yields Rise To 14-Year High—What The Recent Past Tells Us About Impact On US Markets</a>
Why It Matters: Japan's bond market volatility has already raised concerns about global financial stability. Schiff warns that rising JGB yields and a bond crash could ripple through international markets, destabilizing the U.S. economy.
His stark message comes as the Bank of Japan faces pressure to manage inflation without crushing economic growth, a balancing act made tougher by persistent yield increases.
<h2 class="wp-block-heading">JPMorgan Analysts Expect A Ceiling On Yields</h2>
Jason Hunter, JPMorgan&#8217;s head of technical strategy, takes a less alarmist view. He suggests that the yield surge may soon stabilize. 
&#8220;We suspect that 1.24-1.315% area will put a ceiling over 10-year JGBs for the weeks ahead,&#8221; he said in a Tuesday research note.
Hunter advised investors to watch for a settling trend near these levels, potentially easing pressure on U.S. Treasuries and broader markets.
Whether JGB yields will trigger chaos like Schiff says, or settle into calm, remains to be seen. But one thing is clear: plenty of eyes in the financial world are on Japan.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/bonds/25/01/42996183/trump-faces-bond-market-pressure-as-10-year-yields-near-5-challenging-economic-agenda">Trump Faces Bond Market Pressure As 10-Year Yields Near 5%, Challenging Economic Agenda</a></li>
</ul>
Image: Shutterstock

Analyst Color

Asia

Macro Economic Events

Bonds

Economics

Analyst Ratings

Peter Schiff Warns 'A Financial Tsunami' Will Crash US Markets As Japan's Yields Soar

Providing a diverse range of perspectives from bullish to bearish, 4 analysts have published ratings on Kenvue (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KVUE#NYSE">KVUE</a>) in the last three months.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $24.5, a high estimate of $27.00, and a low estimate of $21.00. Marking an increase of 3.16%, the current average surpasses the previous average price target of $23.75. 
<img src="https://www.benzinga.com/files/images/story/2025/1736971251_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive Kenvue. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Filippo Falorni</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$21.00</td>
<td>$25.00</td>
</tr>
<tr>
<td>Korinne Wolfmeyer</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$26.00</td>
<td>$21.00</td>
</tr>
<tr>
<td>Steve Powers</td>
<td>Deutsche Bank</td>
<td>Lowers</td>
<td>Hold</td>
<td>$24.00</td>
<td>$25.00</td>
</tr>
<tr>
<td>Anna Lizzul</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$27.00</td>
<td>$24.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Kenvue. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Kenvue compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Kenvue's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Capture valuable insights into Kenvue's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/KVUE/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Kenvue analyst ratings.</a>
<h2>About Kenvue</h2>
Kenvue is the world's largest pure-play consumer health company by sales, generating $15 billion in annual revenue. Formerly known as Johnson &amp; Johnson's consumer segment, Kenvue spun off and went public in May 2023. It operates in a variety of silos within consumer health, such as cough, cold and allergy care, pain management, face and body care, and oral care, as well as women's health. Its portfolio includes a wide array of some of the most well-known brands in the space, including Tylenol, Listerine, Johnson's, Aveeno, and Neutrogena. Despite playing in a fragmented industry with intense competition and ever-changing consumer preferences, many of Kenvue's brands are the global leader in their respective segment thanks to their strong brand power.
<h3>Financial Milestones: Kenvue's Journey</h3>
Market Capitalization Analysis: With an elevated market capitalization, the company stands out above industry averages, showcasing substantial size and market acknowledgment.
Decline in Revenue: Over the 3 months period, Kenvue faced challenges, resulting in a decline of approximately -0.41% in revenue growth as of 30 September, 2024. This signifies a reduction in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Consumer Staples sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 9.82%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 3.68%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): Kenvue's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 1.44%, the company showcases efficient use of assets and strong financial health.
Debt Management: Kenvue's debt-to-equity ratio is below the industry average at 0.83, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>Analyst Ratings: What Are They?</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

KVUE

What Analysts Are Saying About Kenvue Stock

7 analysts have shared their evaluations of Noble Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NE#NYSE">NE</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $44.29, along with a high estimate of $64.00 and a low estimate of $37.00. This current average has decreased by 16.17% from the previous average price target of $52.83. 
<img src="https://www.benzinga.com/files/images/story/2025/1736971243_0.png" alt="price target chart" />
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
The standing of Noble Corp among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>James West</td>
<td>Evercore ISI Group</td>
<td>Lowers</td>
<td>In-Line</td>
<td>$41.00</td>
<td>$64.00</td>
</tr>
<tr>
<td>Eddie Kim</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$42.00</td>
<td>$47.00</td>
</tr>
<tr>
<td>Arun Jayaram</td>
<td>JP Morgan</td>
<td>Announces</td>
<td>Neutral</td>
<td>$37.00</td>
<td>-</td>
</tr>
<tr>
<td>Nikhil Gupta</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Buy</td>
<td>$40.00</td>
<td>$45.00</td>
</tr>
<tr>
<td>Charles Minervino</td>
<td>Susquehanna</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$38.00</td>
<td>$40.00</td>
</tr>
<tr>
<td>James West</td>
<td>Evercore ISI Group</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$64.00</td>
<td>$67.00</td>
</tr>
<tr>
<td>Eddie Kim</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$48.00</td>
<td>$54.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Noble Corp. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Noble Corp compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of Noble Corp's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Noble Corp's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/NE/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Noble Corp analyst ratings.</a>
<h2>Delving into Noble Corp's Background</h2>
Noble Corp PLC is an offshore drilling contractor for the oil and gas industry that provides contract drilling services to the international oil and gas industry with its fleet of mobile offshore drilling units. The company focuses on a high-specification fleet of floating and jackup rigs and the deployment of its drilling rigs in oil and gas basins around the world.
<h3>Noble Corp's Economic Impact: An Analysis</h3>
Market Capitalization Analysis: With a profound presence, the company's market capitalization is above industry averages. This reflects substantial size and strong market recognition.
Positive Revenue Trend: Examining Noble Corp's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 14.78% as of 30 September, 2024, showcasing a substantial increase in top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Energy sector.
Net Margin: Noble Corp's net margin is impressive, surpassing industry averages. With a net margin of 7.65%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Noble Corp's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 1.41% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): Noble Corp's ROA stands out, surpassing industry averages. With an impressive ROA of 0.9%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.42.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Noble Corp Stock: A Deep Dive Into Analyst Perspectives (7 Ratings)

15 analysts have shared their evaluations of Exelixis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXEL#NASDAQ">EXEL</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">6</td>
<td align="right">6</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">3</td>
<td align="right">4</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for Exelixis, presenting an average target of $37.13, a high estimate of $42.00, and a low estimate of $29.00. This current average reflects an increase of 15.06% from the previous average price target of $32.27. 
<img src="https://www.benzinga.com/files/images/story/2025/1736971236_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
A clear picture of Exelixis's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Asthika Goonewardene</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$42.00</td>
<td>$38.00</td>
</tr>
<tr>
<td>Silvan Tuerkcan</td>
<td>JMP Securities</td>
<td>Raises</td>
<td>Market Outperform</td>
<td>$41.00</td>
<td>$34.00</td>
</tr>
<tr>
<td>Joseph Catanzaro</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$37.00</td>
<td>$36.00</td>
</tr>
<tr>
<td>Robert Burns</td>
<td>HC Wainwright &amp; Co.</td>
<td>Raises</td>
<td>Buy</td>
<td>$40.00</td>
<td>$29.00</td>
</tr>
<tr>
<td>Michael Schmidt</td>
<td>Guggenheim</td>
<td>Raises</td>
<td>Buy</td>
<td>$42.00</td>
<td>$33.00</td>
</tr>
<tr>
<td>Etzer Darout</td>
<td>BMO Capital</td>
<td>Raises</td>
<td>Market Perform</td>
<td>$40.00</td>
<td>$36.00</td>
</tr>
<tr>
<td>Jason Gerberry</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Neutral</td>
<td>$39.00</td>
<td>$35.00</td>
</tr>
<tr>
<td>Michael Schmidt</td>
<td>Guggenheim</td>
<td>Raises</td>
<td>Buy</td>
<td>$33.00</td>
<td>$32.00</td>
</tr>
<tr>
<td>Sudan Loganathan</td>
<td>Stephens &amp; Co.</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$29.00</td>
<td>$23.00</td>
</tr>
<tr>
<td>Joseph Catanzaro</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$36.00</td>
<td>$33.00</td>
</tr>
<tr>
<td>Gregory Renza</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$34.00</td>
<td>$34.00</td>
</tr>
<tr>
<td>Asthika Goonewardene</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$38.00</td>
<td>$33.00</td>
</tr>
<tr>
<td>Derek Archila</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$36.00</td>
<td>$32.00</td>
</tr>
<tr>
<td>Etzer Darout</td>
<td>BMO Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$36.00</td>
<td>$29.00</td>
</tr>
<tr>
<td>Yaron Werber</td>
<td>TD Cowen</td>
<td>Raises</td>
<td>Buy</td>
<td>$34.00</td>
<td>$27.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Exelixis. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Exelixis compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Exelixis's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/EXEL/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Exelixis analyst ratings.</a>
<h2>Discovering Exelixis: A Closer Look</h2>
Exelixis is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its lead molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.
<h3>Understanding the Numbers: Exelixis's Finances</h3>
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
Positive Revenue Trend: Examining Exelixis's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 14.33% as of 30 September, 2024, showcasing a substantial increase in top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Exelixis's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 21.87%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Exelixis's ROE stands out, surpassing industry averages. With an impressive ROE of 5.37%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): Exelixis's ROA excels beyond industry benchmarks, reaching 4.12%. This signifies efficient management of assets and strong financial health.
Debt Management: Exelixis's debt-to-equity ratio is below the industry average. With a ratio of 0.09, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>Analyst Ratings: What Are They?</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

EXEL

15 Analysts Have This To Say About Exelixis

Ratings for AutoNation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AN#NYSE">AN</a>) were provided by 4 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $184.75, a high estimate of $200.00, and a low estimate of $170.00. This upward trend is evident, with the current average reflecting a 1.37% increase from the previous average price target of $182.25.
<img src="https://www.benzinga.com/files/images/story/2025/1736971228_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive AutoNation. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Colin Langan</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$170.00</td>
<td>$169.00</td>
</tr>
<tr>
<td>Glenn Chin</td>
<td>Seaport Global</td>
<td>Raises</td>
<td>Buy</td>
<td>$200.00</td>
<td>$180.00</td>
</tr>
<tr>
<td>Ali Faghri</td>
<td>Guggenheim</td>
<td>Lowers</td>
<td>Buy</td>
<td>$189.00</td>
<td>$190.00</td>
</tr>
<tr>
<td>Rajat Gupta</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$180.00</td>
<td>$190.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to AutoNation. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of AutoNation compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of AutoNation's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
Capture valuable insights into AutoNation's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/AN/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on AutoNation analyst ratings.</a>
<h2>About AutoNation</h2>
AutoNation is the second largest automotive dealer in the United States, with 2023 revenue of about $27 billion and over 250 dealerships, plus 53 collision centers. The firm also has 23 AutoNation USA used-vehicle stores, a captive lender, four auction sites, and three parts distributors all across 21 states primarily in Sunbelt metropolitan areas. New-vehicle sales account for nearly half of revenue; the company also sells used vehicles, parts, and repair services as well as auto financing. The company (formerly Republic Industries) spun off its waste management unit (Republic Services) in 1999 and its car rental businesses (ANC Rental) in 2000. Wayne Huizenga founded the company in the 1990s to bring the rollup acquisition strategy to auto retailing, which has proved to be a smart move.
<h3>AutoNation: A Financial Overview</h3>
Market Capitalization: Boasting an elevated market capitalization, the company surpasses industry averages. This signals substantial size and strong market recognition.
Negative Revenue Trend: Examining AutoNation's financials over 3 months reveals challenges. As of 30 September, 2024, the company experienced a decline of approximately -4.45% in revenue growth, reflecting a decrease in top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Consumer Discretionary sector.
Net Margin: AutoNation's net margin is impressive, surpassing industry averages. With a net margin of 2.82%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): AutoNation's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 8.16%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): AutoNation's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 1.44% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: AutoNation's debt-to-equity ratio is below the industry average. With a ratio of 3.69, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>What Are Analyst Ratings?</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Forecasting The Future: 4 Analyst Projections For AutoNation

S&amp;P Global's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPGI#NYSE">SPGI</a>) short percent of float has fallen 15.89% since its last report. The company recently reported that it has 2.79 million shares sold short, which is 0.9% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.3 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>S&amp;P Global Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1736971224_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for S&amp;P Global has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing S&amp;P Global's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, S&amp;P Global's peer group average for short interest as a percentage of float is 2.93%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

SPGI

(SPGI) - Analyzing S&P Global's Short Interest

Providing a diverse range of perspectives from bullish to bearish, 7 analysts have published ratings on Gambling.com Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GAMB#NASDAQ">GAMB</a>) in the last three months.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">6</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated Gambling.com Gr and provided 12-month price targets. The average target is $17.0, accompanied by a high estimate of $21.00 and a low estimate of $14.00. This upward trend is apparent, with the current average reflecting a 10.89% increase from the previous average price target of $15.33.
<img src="https://www.benzinga.com/files/images/story/2025/1736971221_0.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
A comprehensive examination of how financial experts perceive Gambling.com Gr is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>David Katz</td>
<td>Jefferies</td>
<td>Raises</td>
<td>Buy</td>
<td>$21.00</td>
<td>$20.00</td>
</tr>
<tr>
<td>Mike Hickey</td>
<td>Benchmark</td>
<td>Announces</td>
<td>Buy</td>
<td>$16.00</td>
<td>-</td>
</tr>
<tr>
<td>David Katz</td>
<td>Jefferies</td>
<td>Raises</td>
<td>Buy</td>
<td>$20.00</td>
<td>$18.00</td>
</tr>
<tr>
<td>Chad Beynon</td>
<td>Macquarie</td>
<td>Raises</td>
<td>Outperform</td>
<td>$16.00</td>
<td>$14.00</td>
</tr>
<tr>
<td>Ryan Sigdahl</td>
<td>Craig-Hallum</td>
<td>Raises</td>
<td>Buy</td>
<td>$16.00</td>
<td>$14.00</td>
</tr>
<tr>
<td>Jeffrey Stantial</td>
<td>Stifel</td>
<td>Raises</td>
<td>Buy</td>
<td>$14.00</td>
<td>$13.00</td>
</tr>
<tr>
<td>Barry Jonas</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$16.00</td>
<td>$13.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Gambling.com Gr. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Gambling.com Gr compared to the broader market.</li>
<li>Price Targets: Analysts provide insights into price targets, offering estimates for the future value of Gambling.com Gr's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Gambling.com Gr's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/GAMB/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Gambling.com Gr analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>About Gambling.com Gr</h2>
Gambling.com Group Ltd is a multi-award-winning performance marketing company and a provider of digital marketing services in the online gambling industry. Its principal focus is on online casino and online sports betting and the fantasy sports industry. It generates revenue by referring online gamblers to online gambling operators.
<h3>Financial Insights: Gambling.com Gr</h3>
Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: Over the 3 months period, Gambling.com Gr showcased positive performance, achieving a revenue growth rate of 36.92% as of 30 September, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Communication Services sector.
Net Margin: Gambling.com Gr's net margin excels beyond industry benchmarks, reaching 26.49%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Gambling.com Gr's ROE excels beyond industry benchmarks, reaching 6.85%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): Gambling.com Gr's ROA stands out, surpassing industry averages. With an impressive ROA of 4.68%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.24.
<h2>The Basics of Analyst Ratings</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

GAMB

Analyst Expectations For Gambling.com Gr's Future

Lennox Intl's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LII#NYSE">LII</a>) short percent of float has risen 35.98% since its last report. The company recently reported that it has 1.45 million shares sold short, which is 5.14% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.53 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Lennox Intl Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1736971219_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Lennox Intl has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Lennox Intl's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Lennox Intl's peer group average for short interest as a percentage of float is 3.72%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Looking Into Lennox Intl's Recent Short Interest

FirstCash Hldgs's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FCFS#NYSE">FCFS</a>) short percent of float has fallen 12.42% since its last report. The company recently reported that it has 733 thousand shares sold short, which is 2.61% of all regular shares that are available for trading. Based on its trading volume, it would take traders 3.37 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>FirstCash Hldgs Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1736971214_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for FirstCash Hldgs has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing FirstCash Hldgs's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, FirstCash Hldgs's peer group average for short interest as a percentage of float is 6.73%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

FCFS

Peering Into FirstCash Hldgs's Recent Short Interest

Micron Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MU#NASDAQ">MU</a>) has outperformed the market over the past 10 years by 1.94% on an annualized basis producing an average annual return of 13.31%. Currently, Micron Technology has a market capitalization of $110.75 billion. 
Buying $1000 In MU: If an investor had bought $1000 of MU stock 10 years ago, it would be worth $3,489.35 today based on a price of $99.40 for MU at the time of writing.
<h3>Micron Technology's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1736971211_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much $1000 Invested In Micron Technology 10 Years Ago Would Be Worth Today

Analysts' ratings for PotlatchDeltic (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCH#NASDAQ">PCH</a>) over the last quarter vary from bullish to bearish, as provided by 5 analysts.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for PotlatchDeltic, revealing an average target of $47.2, a high estimate of $51.00, and a low estimate of $44.00. Observing a downward trend, the current average is 4.65% lower than the prior average price target of $49.50. 
<img src="https://www.benzinga.com/files/images/story/2025/1736971209_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
The perception of PotlatchDeltic by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Anthony Pettinari</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Buy</td>
<td>$46.00</td>
<td>$52.00</td>
</tr>
<tr>
<td>Michael Roxland</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Hold</td>
<td>$44.00</td>
<td>$45.00</td>
</tr>
<tr>
<td>Buck Horne</td>
<td>Raymond James</td>
<td>Announces</td>
<td>Outperform</td>
<td>$45.00</td>
<td>-</td>
</tr>
<tr>
<td>Ketan Mamtora</td>
<td>BMO Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$51.00</td>
<td>$51.00</td>
</tr>
<tr>
<td>Matthew McKellar</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$50.00</td>
<td>$50.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to PotlatchDeltic. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of PotlatchDeltic compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of PotlatchDeltic's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/PCH/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on PotlatchDeltic analyst ratings.</a>
<h2>Unveiling the Story Behind PotlatchDeltic</h2>
PotlatchDeltic Corp is a REIT that owns and manages forestland in Alabama, Arkansas, Idaho, Minnesota, and Mississippi. Potlach operates in three segments. The timberlands segment covers the planting and harvesting of trees, as well as the construction and maintenance of roads. The wood products segment manufactures and distributes lumber, plywood, and other wood products. The real estate segment covers the sales generated from company-owned timberlands, as well as commercial and residential properties. The timberlands and the wood product segments combined drive the majority of the company's revenue.
<h3>Understanding the Numbers: PotlatchDeltic's Finances</h3>
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
Decline in Revenue: Over the 3 months period, PotlatchDeltic faced challenges, resulting in a decline of approximately -3.91% in revenue growth as of 30 September, 2024. This signifies a reduction in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Real Estate sector.
Net Margin: PotlatchDeltic's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of 1.3%, the company may face hurdles in effective cost management.
Return on Equity (ROE): PotlatchDeltic's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of 0.16%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): PotlatchDeltic's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of 0.1%, the company may face hurdles in achieving optimal financial returns.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.5.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Demystifying PotlatchDeltic: Insights From 5 Analyst Reviews

Economic activity expanded slightly to moderately across the Federal Reserve&#8217;s 12 districts during late November and December, yet concerns over looming changes to U.S. immigration and tariff policies cast a shadow on the future, according to the Fed <a href="https://www.benzinga.com/topic/federal-reserve">Beige Book released Wednesday. </a>
The latest Fed Beige Book report highlighted moderate growth in consumer spending, strong holiday sales and rising wages.
According to anecdotal economic insights from businesses and other contacts across the country, several Fed districts showed potential economic headwinds tied to expected policy shifts under President-elect Donald Trump.
<h3 class="wp-block-heading">How Expected Tariffs, Immigration Policies Shape Business Sentiment</h3>
Businesses are increasingly wary of the Trump administration&#8217;s plans to tighten immigration rules and impose steep tariffs. Trump has floated the idea of raising tariffs on Chinese goods to as much as 60% and applying 10% universal tariffs on imports from other nations.
The manufacturing sector appears particularly vulnerable, with contacts reporting efforts to stockpile raw materials in anticipation of higher tariffs.
Additionally, some businesses fear that restrictions on immigration could exacerbate labor shortages, especially in industries like construction and agriculture.
Business leaders across industries within the New York Fed District &#8220;expressed concern that potential import tariffs would push up prices,&#8221; the Beige Book stated.
In the Richmond Fed District, firms from various sectors expressed concerns and uncertainties about tariffs, port worker strikes and overall economic conditions heading into the new year.
<h3 class="wp-block-heading">Wage Growth Picks Up, Inflationary Pressures Remain Modest</h3>
The labor market showed signs of strength, with wage growth accelerating to a moderate pace across most districts. Yet businesses reported growing uncertainty about future staffing needs, especially in light of potential policy changes.
Prices rose modestly overall, with businesses reporting a mix of flat, moderate or even declining selling prices in certain sectors like retail and manufacturing.
Input costs, particularly for health insurance and fuel, continued to climb, and some contacts predicted that higher tariffs would contribute to broader inflation in 2025.
While inflationary pressures remain contained for now, many businesses are bracing for price hikes if the new tariffs go into effect.
The agricultural sector struggled under weak farm incomes and adverse weather conditions. The spread of avian flu further tightened egg supplies, leading to a spike in prices. Energy activity, meanwhile, was mixed, with optimism about 2025 tempered by uncertainty over global demand.
Despite these challenges, the Beige Book revealed cautious optimism for the year ahead. More contacts reported a positive outlook for 2025 than a negative one, reflecting the resilience of the U.S. economy in the face of shifting political landscape.
<h3 class="wp-block-heading">Market Reactions</h3>
Markets showed little reaction to the Fed Beige Book release. The S&amp;P 500, tracked by the SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>), maintained its session gains of 1.8%.
Tech stocks rallied further during early afternoon trading in New York. The Invesco QQQ Trust, Series 1 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>) was 2.3% higher, eyeing its strongest session since Nov. 6, 2024, when tech stocks showed a post-election rally.
The U.S. dollar index was also little moved, with the Invesco DB USD Index Bullish Fund ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UUP#NYSE">UUP</a>) down 0.1% for the day.
Crude oil added gains, with the West Texas Intermediate light crude up by over 3% to $80 a barrel by 2:20 p.m. ET. 
Read now: 
<ul>
<li><a href="https://www.benzinga.com/news/earnings/25/01/43007354/big-banks-crush-q4-earnings-forecasts-financial-stocks-set-for-biggest-1-day-rally-since-trumps-election">Big Banks Crush Q4 Earnings Forecasts: Financial Stocks Set For Biggest 1-Day Rally Since Trump&#8217;s Election</a></li>
</ul>
Photo via Shutterstock.

Broad U.S. Equity ETFs

Federal Reserve

ETFs

PowerShares DB US Dollar Index Bullish Fund

Fed Beige Book Flags Moderate Growth, Yet Tariffs, Immigration Policies Spark Concerns

Pacific Gas &amp; Electric Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PCG#NYSE">PCG</a>) stock has recently faced volatility amid shifting investor sentiment <a href="https://www.benzinga.com/topic/utilities">and market dynamics.</a>
Activist investor Dan Loeb&#8216;s hedge fund, Third Point, held 49.7 million shares in utility company Pacific Gas &amp; Electric Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PCG#NYSE">PCG</a>) as of Sept. 30, 2024, making it the fund&#8217;s largest <a href="https://www.benzinga.com/news/large-cap/25/01/42788070/hedge-fund-giant-dan-loebs-pge-bet-beats-market">holding at the time.</a>
On Jan. 13, 2025, BMO Capital analyst James M. Thalacker initiated coverage on the company with an Outperform and<a href="https://www.benzinga.com/quote/pcg/analyst-ratings" target="_blank" rel="noreferrer noopener"> a price target of $21</a>.
The analyst writes that he views PCG shares as a core holding in the regulated utility sector, offering investors a rare combination of deep value and premium, visible growth potential.
Thalacker&#8217;s five-year forecast (2024-2028) projects EPS growth of around 9.2% and rate base growth of about 10%, aligning with the company's long-term EPS target of at least 9%.
Also, on Dec. 17, JPMorgan analysts Jeremy Tonet and Richard W. Sunderland stated that they believe PG&amp;E's wildfire mitigation investments, data center pipeline and re-rating potential <a href="https://www.benzinga.com/news/large-cap/25/01/42788070/hedge-fund-giant-dan-loebs-pge-bet-beats-market" target="_blank" rel="noreferrer noopener">could drive substantial gains</a>. 
Notably, last month, the Department of Energy disclosed plans to provide Pacific Gas &amp; Electric with a record $15 billion loan guarantee to strengthen its electrical grid and support climate resiliency initiatives.
If finalized, the loan guarantee for PG&amp;E&#8217;s Project Polaris will support hydropower, battery storage, transmission upgrades, and virtual power plants across its service area.
The Energy Department said that these infrastructure investments will enable PG&amp;E to address projected load growth, enhance electric reliability, <a target="_blank" href="https://www.energy.gov/lpo/articles/lpo-announces-conditional-commitment-pacific-gas-electric-company-expand-hydropower" rel="noreferrer noopener">and</a> lower costs for consumers throughout California.
Earlier, during its third-quarter earnings call, PCG raised its five-year capital investment plan by $1 billion, bringing the total to $63 billion for <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/n41800512/pg-e-corporation-reports-strong-third-quarter-results-strengthens-2024-guidance-initiates-2025-gui" rel="noreferrer noopener">the 2024-2028 period</a>.
The company also reaffirmed its equity issuance guidance <a href="https://www.benzinga.com/calendars/guidance">of $3 billion for 2025-2028</a>.
The company expects to release its fourth-quarter earnings <a target="_blank" href="https://www.benzinga.com/earnings" rel="noreferrer noopener">results in February 2025</a>.
Investors can gain exposure to the stock via VanEck Uranium and Nuclear ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NLR#NYSE">NLR</a>) and Themes ETF Trust Themes Uranium &amp; Nuclear ETF (BATS:<a class="ticker" href="https://www.benzinga.com/stock/URAN#BATS">URAN</a>).
Price Action: PCG shares are up 4.71% at $17 at last check Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/01/42983439/la-braces-for-another-extreme-fire-weather-scenario-multiple-lawsuits-filed-against-edison-over-eaton-fire-damages" target="_blank" rel="noreferrer noopener">LA Braces For More &#8216;Extreme Fire Weather,&#8217; Multiple Lawsuits Filed Against Edison Over Eaton Fire Damages</a></li>
</ul>
Photo: Shutterstock

Equities

Large Cap

Hedge Funds

Initiation

Themes ETF Trust Themes Uranium & Nuclear ETF

URAN

Dan Loeb's PG&E Play: Growth, Resilience, And $63 Billion Investments

BRNS, UPC and KWE among mid-day movers

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on eFFECTOR Therapeutics (EFTR – Research Report), Adag...

Analysts Offer Insights on Healthcare Companies: eFFECTOR Therapeutics (EFTR), Adagene (ADAG) and Aquestive Therapeutics (AQST)

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Marinus (MRNS – Research Report), uniQure (QURE – Re...

Analysts Offer Insights on Healthcare Companies: Marinus (MRNS), uniQure (QURE) and eFFECTOR Therapeutics (EFTR)

Stifel Nicolaus analyst Benjamin Burnett maintained a Buy rating on eFFECTOR Therapeutics (EFTR – Research Report) today and set a price target of ...

Stifel Nicolaus Remains a Buy on eFFECTOR Therapeutics (EFTR)

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
eFFECTOR Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/eftr-stock-quote/">EFTR</a>) just reported results for the first quarter of 2024.<ul><li>eFFECTOR Therapeutics reported earnings per share of -$2.16. This met the analyst estimate for EPS of -$2.16.</li><li>The company did not report any revenue for the quarter.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT802110">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT766411">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/earning-results/2024/05/eftr-stock-earnings-effector-therapeutics-for-q1-of-2024/">EFTR Stock Earnings: eFFECTOR Therapeutics Meets EPS for Q1 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

EFTR Stock Earnings: eFFECTOR Therapeutics Meets EPS for Q1 2024

eFFECTOR Therapeutics GAAP EPS of -$2.16 beats by $0.01

eFFECTOR Therapeutics to wind down operations, expects to be delisted from Nasdaq

The latest update is out from eFFECTOR Therapeutics (EFTR). eFFECTOR Therapeutics, Inc. is in the process of winding down operations, leading to th...

eFFECTOR Therapeutics Initiates Wind-Down and Leadership Change

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
It&rsquo;s time to dive into the biggest pre-market stock movers as we check out all of the latest news happening on Wednesday morning!



Moving stocks this morning are patent news, a new investment, proposed public offerings and more.



Let&rsquo;s get into that news below!



<h2>Biggest Pre-Market Stock Movers: 10 Top Gainers</h2>



<ol><li>Syntec Optics (NASDAQ:<a href="https://investorplace.com/stock-quotes/optx-stock-quote/">OPTX</a>) stock is rocketing more than 248% alongside heavy pre-market trading.</li>



<li>Anew Medical (NASDAQ:<a href="https://investorplace.com/stock-quotes/wena-stock-quote/">WENA</a>) shares are soaring over 75% after <a href="https://www.nasdaq.com/press-release/anew-medical-inc-secures-key-patent-europe-human-klotho-gene-rna-slice-variant-and">securing a key patent in Europe</a>.</li>



<li>Volcon (NASDAQ:<a href="https://investorplace.com/stock-quotes/vlcn-stock-quote/">VLCN</a>) stock is surging more than 36% as it <a href="https://investorplace.com/2024/06/why-is-volcon-vlcn-stock-up-60-today/">continues yesterday&rsquo;s rally</a>.</li>



<li>Rivian Automotive (NASDAQ:<a href="https://investorplace.com/stock-quotes/rivn-stock-quote/">RIVN</a>) shares are gaining over 36% on a <a href="https://www.nytimes.com/2024/06/25/business/volkswagen-rivian-vw-investment.html">$5 billion investment</a>.</li>



<li>China Natural Resources (NASDAQ:<a href="https://investorplace.com/stock-quotes/chnr-stock-quote/">CHNR</a>) stock is increasing more than 32% with strong trading this morning.</li>



<li>Savara (NASDAQ:<a href="https://investorplace.com/stock-quotes/svra-stock-quote/">SVRA</a>) shares are rising over 26% on a <a href="https://seekingalpha.com/news/4119362-savara-stock-surges-trial-win-lead-asset?source=content_type%3Areact%7Cfirst_level_url%3Amarket-news%7Csection_asset%3Amain">positive clinical trial</a>.</li>



<li>Talphera (NASDAQ:<a href="https://investorplace.com/stock-quotes/tlph-stock-quote/">TLPH</a>) stock is heading more than 21% higher on Wednesday morning.</li>



<li>eFFECTOR Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/eftr-stock-quote/">EFTR</a>) shares are climbing over 18% even as it plans to <a href="https://finance.yahoo.com/news/effector-therapeutics-announces-wind-down-110000717.html">wind down operations</a>.</li>



<li>Golden Matrix (NASDAQ:<a href="https://investorplace.com/stock-quotes/gmgi-stock-quote/">GMGI</a>) stock is jumping more than 15% today.</li>



<li>Faraday Future (NASDAQ:<a href="https://investorplace.com/stock-quotes/ffie-stock-quote/">FFIE</a>) shares are up over 14% <a href="https://investorplace.com/2024/06/faraday-future-stock-shocker-from-ev-maker-to-china-u-s-auto-middleman/">on survival plans</a>.</li>
</ol><h2>10 Top Losers</h2>



<ol><li>NextTrip (NASDAQ:<a href="https://investorplace.com/stock-quotes/ntrp-stock-quote/">NTRP</a>) stock is diving more than 24% without any recent news to report.</li>



<li>GRI Bio (NASDAQ:<a href="https://investorplace.com/stock-quotes/gri-stock-quote/">GRI</a>) shares are tumbling over 15% on a <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=318415310&amp;type=PDF&amp;symbol=GRI&amp;cdn=40db9b65c5660c095bf51f08f72c725f&amp;companyName=GRI+Bio+Inc.&amp;formType=S-1%2FA&amp;formDescription=%5BAmend%5D+General+form+for+registration+of+securities+under+the+Securities+Act+of+1933&amp;dateFiled=2024-06-26">proposed public offering</a>.</li>



<li>Taysha Gene Therapies (NASDAQ:<a href="https://investorplace.com/stock-quotes/tsha-stock-quote/">TSHA</a>) stock is taking a 14% beating on <a href="https://www.nasdaq.com/press-release/taysha-gene-therapies-announces-proposed-public-offering-common-stock-and-pre-funded">public offering plans</a>.</li>



<li>Oblong (NASDAQ:<a href="https://investorplace.com/stock-quotes/oblg-stock-quote/">OBLG</a>) shares are sliding more than 12% despite a lack of news this morning.</li>



<li>Hanryu (NASDAQ:<a href="https://investorplace.com/stock-quotes/hryu-stock-quote/">HRYU</a>) stock is decreasing over 11% on Wednesday.</li>



<li>Hamilton Beach Brands (NYSE:<a href="https://investorplace.com/stock-quotes/hbb-stock-quote/">HBB</a>) shares are dropping more than 10% today.</li>



<li>GlycoMimetics (NASDAQ:<a href="https://investorplace.com/stock-quotes/glyc-stock-quote/">GLYC</a>) stock is falling over 10% <a href="https://finance.yahoo.com/news/senior-vp-chief-medical-officer-100744620.html">despite insider buying</a>.</li>



<li>Geovax Labs (NASDAQ:<a href="https://investorplace.com/stock-quotes/govx-stock-quote/">GOVX</a>) shares are slipping more than 9% today.</li>



<li>Concord Medical Services (NYSE:<a href="https://investorplace.com/stock-quotes/ccm-stock-quote/">CCM</a>) stock is dipping over 9% this morning.</li>



<li>DermTech (NASDAQ:<a href="https://investorplace.com/stock-quotes/dmtk-stock-quote/">DMTK</a>) shares close out our pre-market stock movers down more than 9% as they <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=318404814&amp;type=PDF&amp;symbol=DMTK&amp;cdn=2f95604b7d0b2db1ef0d52c1cc04ae14&amp;companyName=DermTech+Inc&amp;formType=8-K&amp;formDescription=Current+report+pursuant+to+Section+13+or+15%28d%29&amp;dateFiled=2024-06-20">prepare for delisting tomorrow</a>.</li>
</ol>On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT802110">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT766411">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/2024/06/todays-biggest-pre-market-stock-movers-10-top-gainers-and-losers-on-wednesday-june-26th/">Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
As the stock market hits new highs in July, investors are riding a wave of optimism, closely tracking climbing indexes. Yet, beneath this bullish surface, some publicly traded companies are becoming bankruptcy risk stocks as they&rsquo;re grappling with the stark reality of financial distress.



Of course, investing in stocks of companies that have filed for bankruptcy carries notable risks. While there are scenarios where strategic asset sales or restructuring might present short-term gains, such investments are often perilous. The likelihood of losing the entire investment is high, as bankruptcy proceedings can leave shareholders with nothing.



In this article, I will present three publicly traded companies that have become bankruptcy risk stocks. Whether these companies failed to adapt to changing times, leading to deteriorating financials, or were crippled by unsustainable debt loads exacerbated by rising interest rates, their investment cases have gone down the drain. Although these stocks might still have some residual value at their current levels, they are best avoided due to the substantial bankruptcy risks involved.



<h2>Chicken Soup for the Soul Entertainment (CSSE)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2024/04/chicken-soup-csse-stock-1600-300x169.jpg" alt="Chicken Soup for the Soul Entertainment (CSSE) logo displayed on phone, representing CSSE stock"><div>Source: shutterstock.com/rafapress</div></div>Chicken Soup for the Soul Entertainment (NASDAQ:<a href="https://investorplace.com/stock-quotes/csse-stock-quote/">CSSE</a>) operated a diversified entertainment business model, producing, acquiring, and distributing video content via its own streaming platforms and syndication deals. The company leveraged its well-known brand to create inspirational and family-friendly content, aiming to carve a niche in the crowded streaming market.



However, Chicken Soup&rsquo;s strategy faced considerable challenges, leading to its eventual bankruptcy. The company sustained unsustainable losses due to high operational costs and intense competition from major streaming giants. To cover these losses and fund its growth, the company engaged in massively dilutive stock issuances, which deteriorated shareholder value. Its share count leaped from <a href="https://app.koyfin.com/share/4c2477d2e0">11.5 million in 2017 to over 32 million</a> at the end of Q1.



Chicken Soup accumulated a massive debt position, <a href="https://app.koyfin.com/share/b485aa9af0">standing at $579.3 million</a> at the end of Q1, primarily from expansions and acquisitions. This debt became increasingly burdensome as rising interest rates exacerbated the interest expense, further weakening the company&rsquo;s financial health. After failing to pay its employees, Chicken Soup <a href="https://www.nytimes.com/2024/06/30/business/chicken-soup-for-soul-bankruptcy.html">filed for bankruptcy just over a week ago</a>.



<h2>eFFECTOR Therapeutics (EFTR)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/10/biotechnology1600-300x169.png" alt="Biotechnology stocks, biomedical stocks"><div>Source: aslysun / Shutterstock.com</div></div>eFFECTOR Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/eftr-stock-quote/">EFTR</a>) was a biotechnology company focused on the development of novel therapies for cancer patients by targeting the process of protein translation. Their innovative approach aimed to disrupt cancer cell growth and proliferation, positioned eFFECTOR as a potential leader in oncology therapeutics.



Despite its somewhat promising scientific foundation, including innovative approaches to disrupt cancer cell growth, the company faced insurmountable challenges that ultimately led to its downfall. In April, eFFECTOR Therapeutics <a href="https://www.clinicaltrialsarena.com/news/effector-shelves-tomivosertib-in-nsclc-following-phase-ii-failure/#:~:text=eFFECTOR%20Therapeutics%20has%20discontinued%20the,NSCLC)%20following%20negative%20topline%20results.">announced</a> its decision to halt the development of Tomivosertib for treating frontline non-small cell lung cancer. This hard decision came after disappointing results from a mid-stage trial, where the therapy failed to meet its endpoints.



This setback affected eFFECTOR&rsquo;s pipeline hugely, as Tomivosertib was a key candidate in its portfolio. Ultimately, no bullish reason to keep eFFECTOR&rsquo;s investment case promising remained, leading to the downfall of its stock price. With expenses continuing to pile up, bankruptcy was inevitable.



<h2>Delta Apparel (DLAPQ)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/07/xl-clothing-clothes-dxlg-1600-300x169.jpg" alt="A hand reaches for an article of clothing on a hanger from a rack labeled XL."><div>Source: christinarosepix / Shutterstock.com</div></div>The final company on my list of bankruptcy risk stocks is Delta Apparel (OTCMKTS:<a href="https://investorplace.com/stock-quotes/dlapq-stock-quote/">DLAPQ</a>). A small-cap stock even before its financial distress set in, Delta Apparel was known for manufacturing and selling a wide range of activewear, lifestyle, and outdoor apparel via various brands and distribution channels. Some of its largest customers included Walmart (NYSE:<a href="https://investorplace.com/stock-quotes/wmt-stock-quote/">WMT</a>), Target (NYSE:<a href="https://investorplace.com/stock-quotes/tgt-stock-quote/">TGT</a>), Nike (NYSE:<a href="https://investorplace.com/stock-quotes/nike-stock-quote/">NIKE</a>).



Despite its established presence in the industry, the company struggled with declining profitability due to intense competition and shifting consumer preferences. As a result, Delta Apparel&rsquo;s revenue growth stagnated, putting pressure on its margins and, hence, bottom line.



Compounding these issues was Delta Apparel&rsquo;s substantial debt position relative to its size, which peaked at <a href="https://app.koyfin.com/share/652c8fc99a">$252.2 million last year</a>. The company went into a rising interest rate environment when servicing this debt became increasingly expensive. Also, instead of deleveraging, Delta Apparel had previously engaged in share repurchases, which further strained its financial flexibility and ability to manage its debt effectively. At $0.07, Delta stock is best avoided despite any potential fluctuations in its favor, as it faces delisting.



On the date of publication, Nikolaos Sismanis did not hold (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.



On the date of publication, the responsible editor did not have (either directly or indirectly) any positions in the securities mentioned in this article.
<div>Nikolaos Sismanis is a professional research analyst with five years of experience in the field of equity research and financial modeling. Nikolaos has authored over 1,000 stock-related articles that focus on uncovering deep value opportunities, identifying growth stocks at reasonable valuations, and shining a spotlight on overlooked international equities.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	
The post <a href="https://investorplace.com/2024/07/3-publicly-traded-companies-filing-for-bankruptcy-as-july-kicks-off/">3 Publicly Traded Companies Filing for Bankruptcy as July Kicks Off</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

3 Publicly Traded Companies Filing for Bankruptcy as July Kicks Off

ADAG

AQST

BRNS

CHNR

CSSE

DLAPQ

DMTK

EIGR

FFIE

GLYC

GMGI

GOVX

HRYU

KYCH

MGNX

MRNS

NOTV

NTRP

OBLG

OPTX

QURE

REPX

RIVN

SPWH

SVRA

TLPH

TSHA

VLCN

WENA

XTIA

Financing

Press Releases

eFFECTOR Therapeutics Announces $15 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

Opinion

Thinking about buying stock in LAVA Therapeutics, UP Fintech Holding, Babcock & Wilcox Enterprises, Safety Shot, or eFFECTOR Therapeutics?

eFFECTOR Therapeutics Announces Closing of $15 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

eFFECTOR Therapeutics to Present at Oppenheimer 34th Annual Healthcare Life Sciences Conference

eFFECTOR Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

Health Care

eFFECTOR Therapeutics Announces Topline Results of Phase 2 KICKSTART Trial of Tomivosertib Combined with Pembrolizumab in Non-Small Cell Lung Cancer

eFFECTOR Therapeutics to Participate in Upcoming Investor Conference

eFFECTOR Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update

eFFECTOR Therapeutics to Collaborate with the Dana-Farber Cancer Institute on an Investigator-Sponsored Phase 2 Clinical Trial Evaluating Zotatifin as Combination Treatment in ER+ Endometrial Cancer and in Low Grade Serous Ovarian Cancer

eFFECTOR Therapeutics Announces it will Wind Down Operations as it Seeks Strategic Alternatives and Expects to be Delisted from Nasdaq

Comments

eFFECTOR Therapeutics

eFFECTOR Therapeutics (EFTR) Forecast

eFFECTOR Therapeutics (OTC:EFTR) Stock, Quote.Headers.trade-ideas

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga